Further to the announcement on 2 January 2025 (the “2.4 Announcement”) and the update on the potential combination of Poolbeg and HOOKIPA announced on 7 January 2025, the following amendment has been made regarding Gilead Sciences Inc.’s (“Gilead”) participation in the proposed concurrent Fundraise.
Gilead has indicated its intention to vote consistent with the HOOKIPA Board’s recommendation if a formal offer were to be made and to participate in the proposed concurrent Fundraise in an amount up to $8.7495 million, consistent with its current contractual obligations.
All discussions relating to the Potential Combination to date have been non-binding and on a non-exclusive basis, and there can be no assurance that a firm offer will be made or that any transaction will be completed.
Capitalised terms used but not defined in this announcement have the same meanings given to them in the 2.4 Announcement.
|
Enquiries:
|
|
|
Poolbeg Pharma Plc |
+44 (0) 207 183 1499 |
|
Cathal Friel, Chairman |
Website publication
In accordance with Rule 30.4 of the Code, a copy of this announcement will be available on the Company’s website – https://www.poolbegpharma.com/about/investors/rns-news/ and Hookipa’s website – ir.hookipapharma.com/potential-combination – by 12 noon on 13 January 2025.
The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.
